BioNovelus, Inc. Ready to Ship Eco-Friendly Fungicide, CR-10, to Fight Coffee Rust in Costa Rica!

Phoenix, June 22, 2016 (GLOBE NEWSWIRE) -- BioNovelus, Inc. (PINKSHEETS: ONOV) is pleased to announce that four thousand (4,000) bottles of its biodegradable fungicide, CR-10, the answer to killing coffee rust, has been manufactured for delivery to Costa Rica.

Mr. Jean Ekobo, President/CEO of BioNovelus, Inc., says, "This CR-10 allotment is slotted for ongoing tests with our partners, as well as to satisfy pre-orders. This represents a huge milestone for our Company and its shareholders, because it brings BioNovelus closer to Revenue Stage."

“Our tests have shown that one bottle of CR-10 will treat one hectare of a coffee plantation. Coffee farmers will need 3 applications per growing season to effectively and safely kill the coffee rust.”

The chart below shows the market potential for countries that have coffee rust and are perfectly suited for BioNovelus CR-10. Costa Rica, with only its 93,800 hectares of coffee plantations, has consumed 257,667 liters (or bottles) of chemical fungicide to try to control the coffee leaf rust in 2015. Central America, along with Mexico and Colombia, represent a substantial market for BioNovelus non-toxic fungicide CR-10.

980,000 ha
680,000 ha
Honduras282,000 ha
Guatemala276,500 ha
El Salvador152,200 ha
Nicaragua126,200 ha
Costa Rica 93,800 ha
TOTAL2,591,200 hectares

About BioNovelus Inc.
BioNovelus, Inc. (PINKSHEETS: ONOV) is a biotech company that honors the environment with an innovative, cost effective, and disruptive technology-based solution to the problems of safety and cleanliness regarding food production and water supply.

Forward-Looking Statements
This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2015 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.
Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company's control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SOURCE: BioNovelus Inc.

For additional information: Please contact: Nathalie Ekobo, Marketing & Communications Director BioNovelus, Inc. 275 North Gateway Dr. Suite 130 Phoenix, AZ 85034 Skype: +1 602-888-3424

Source:BioNovelus Inc.